SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Denies Somaxon Pharmaceuticals, Inc. Approval for Insomnia Drug

February 27, 2009 | 
1 min read
Feb 26 (Reuters) - Somaxon Pharmaceuticals Inc said the U.S. health regulators denied approval for its experimental treatment for insomnia in the present form and raised several issues regarding the efficacy data of the drug.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Handshake of man and robot. Modern technologies. Art collage.
Artificial intelligence
Amid Layoffs, Delays, FDA Turns to AI for Speedy Reviews
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Trendy halftone collage. A hand holds a ringing alarm clock. Time, hurry up. Vector business concepts for graphic and web design, marketing and print materials, social media. Vector illustration
Regulatory
FDA Delays Continue as Regulator Misses Review Date for GSK’s Nucala
May 9, 2025
 · 
2 min read
 · 
Tristan Manalac
illustration of the ship in the storm, gigantic waves
Special edition
Deep Dive: Biopharma In Turmoil As Peter Marks Forced Out of FDA
May 9, 2025
 · 
2 min read
 · 
Annalee Armstrong
Illustration showing businessman avoiding potholes on way to goal
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
 · 
5 min read
 · 
Angela Gabriel